KRIT1 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant KRIT1.
|Calculated MW||84348 Da|
|Other Names||Krev interaction trapped protein 1, Krev interaction trapped 1, Cerebral cavernous malformations 1 protein, KRIT1, CCM1|
|Target/Specificity||KRIT1 (NP_004903, 637 a.a. ~ 736 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||KRIT1 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a protein containing four ankyrin repeats, a band 4.1/ezrin/radixin/moesin (FERM) domain, and multiple NPXY sequences. The encoded protein is localized in the nucleus and cytoplasm. It binds to integrin cytoplasmic domain-associated protein-1 alpha (ICAP1alpha), and plays a critical role in beta1-integrin-mediated cell proliferation. It associates with junction proteins and RAS-related protein 1A (Rap1A), which requires the encoded protein for maintaining the integrity of endothelial junctions. It is also a microtubule-associated protein and may play a role in microtubule targeting. Mutations in this gene result in cerebral cavernous malformations. Multiple alternatively spliced transcript variants have been found for this gene.
Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Rose JE, et al. Mol Med, 2010 Jul-Aug. PMID 20379614.Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. Stockton RA, et al. J Exp Med, 2010 Apr 12. PMID 20308363.Novel KRIT1/CCM1 mutation in a patient with retinal cavernous hemangioma and cerebral cavernous malformation. Reddy S, et al. Graefes Arch Clin Exp Ophthalmol, 2010 Sep. PMID 20306072.Familial versus sporadic cavernous malformations: differences in developmental venous anomaly association and lesion phenotype. Petersen TA, et al. AJNR Am J Neuroradiol, 2010 Feb. PMID 19833796.C329X in KRIT1 is a founder mutation among CCM patients in Sardinia. Cau M, et al. Eur J Med Genet, 2009 Sep-Oct. PMID 19454328.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.